Medscape9h
New Investigation Casts Doubt on Landmark Ticagrelor Trial
New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...
Investigation raises new concerns over landmark trial for top selling anti-platelet drug
An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...
BMJ1d
Doubts over landmark heart drug trial: ticagrelor PLATO study
A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, Peter Doshi takes a fresh look at the ...
News Medical1d
Controversy surrounds landmark anti-platelet drug trial
An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...
Medscape9d
Prasugrel Bests Ticagrelor in Acute Coronary Syndrome Care
A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite ...
Daily3d
Prasugrel Outperforms Ticagrelor in Reducing Mortality and Stroke in Routine Acute Coronary Syndrome Care: JAMA
Germany: A recent cohort study published in JAMA Network Open has shed light on the comparative outcomes of ticagrelor and ...
Business Insider1mon
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
The goal of DrugSorb-ATR, an investigational medical device, is to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta ®, AstraZeneca) undergoing coronary artery ...
Nature6mon
Ticagrelor in ACS—what does PLATO teach us?
The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...